01 — What is it?
GHRF analogue that stimulates endogenous GH release. Approved in the U.S. for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
Database / Research Profiles / Tesamorelin
RESEARCH PROFILE
TESAMORELIN
Growth-hormone-releasing factor analogue
GH axisStrong human clinical evidence for approved indication
EVIDENCE SNAPSHOTSTRONG HUMAN CLINICAL EVIDENCE FOR APPROVED INDICATION
Established human trials and regulatory history for its approved indication; not a general-purpose performance or anti-aging approval.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
GH axis. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: YESPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Established human trials and regulatory history for its approved indication; not a general-purpose performance or anti-aging approval.
04 — Mechanism / biology
GHRF analogue that stimulates endogenous GH release. Approved in the U.S. for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.